参考文献/References:
[1]Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data [J]. Drug Metab Rev, 2002, 34(1-2): 83-484.
[2]IngelmanSundberg M, Sim S C, Gomez A, RodriguezAntona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects [J]. Pharmacol Ther, 2007, 116(3):496-526.
[3]Zhou S F, Di Y M, Chan E, et al. Clinical pharmacogenetics and potential application in personalized medicine [J]. Curr Drug Metab, 2008,9(8):738-84.
[4]Zhou S F, Liu J P, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact [J]. Drug Metab Rev, 2009, 41(2): 89-295.
[5]IngelmanSundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences,evolutionary aspects and functional diversity [J]. Pharmacogenomics J, 2005, 5(1):6-13.
[6]Goetz M P, Knox S K, Suman V J, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen [J]. Breast Cancer Res Treat, 2007,101(1):113-21.
[7]Madlensky L, Natarajan L, Tchu S, et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes [J]. Clin Pharmacol Ther, 2011, 89(5):718-25.
[8]Hayes D F, Stearns V, Rae J, et al. A model citizen is tamoxifen more effective than aromatase inhibitors if we pick the right patients? [J]. J Natl Cancer Inst, 2008,100(9):610-3.
[9]Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes [J]. J Clin Oncol, 2007, 25(33):5187-93.
[10]Azoulay L, Dell’Aniello S, Huiart L, et al. Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence [J]. Breast Cancer Res Treat, 2011,126(3):695-703.
[11]Singh M S, Francis P A, Michael M. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes [J]. Breast, 2011, 20(2):111-8.
[12]成碟, 徐为人, 刘昌孝. 细胞色素P450(CYP450)遗传多态性研究进展[J]. 中国药理学通报, 2006, 22(12): 1409-14.
[12]Cheng D, Xu W R, Liu C X. Progress of research on genetic polymorphism of CYP450s [J]. Chin Pharmacol Bull, 2006, 22(12): 1409-14.
[13]范江, 陆劲松. CYP19基因多态性与乳腺癌风险[J]. 国际肿瘤学杂志, 2006,33(2):128-31.
[13]Fan J, Lu J S. CYP19 gene polymorphism and the risk of breast cancer [J]. Int J Oncol, 2006, 33(2):128-31.
[14]王晓稼, 邵喜英. 乳腺癌CYP19基因研究进展[J]. 实用肿瘤杂志, 2007,22(2):178-81.
[14]Wang X J, Shao X Y. Progress in breast cancer CYP19 gene [J]. J Pract Oncol, 2007,22(2):178-81.
[15]Colomer R, Monzo M, Tusquets I, et al. A singlenucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma [J]. Clin Cancer Res, 2008,14(3): 811-6.
[16]Ma C X, Adjei A A, Salavaggione O E, et al. Human aromatase: gene resequencing and functional genomics [J].Cancer Res, 2005, 65(23): 11071-82.
[17]Wang L, Ellsworth K A, Moon I, et al. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors [J]. Cancer Res, 2010, 70(1): 319-28.
[18]Fasching P A, Loehberg C R, Strissel P L, et al. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients [J]. Breast Cancer Res Treat, 2008, 112(1):89-98.
[19]Park I H, Lee Y S, Lee K S, et al. Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer [J]. Cancer Chemother Pharmacol, 2011,68(5): 1263-71.
[20]Zhou D, Afzelius L, Grimm S W, et al. Comparison of methods for the prediction of the metabolic sites for CYP3A4mediated metabolic reactions [J]. Drug Metab Dispos, 2006, 34(6): 976-83.
[21]Tran A, Jullien V, Alexandre J, et al. Pharmacokinetics and toxicity of docetaxel:Role of CYP3A, MDR1, and GST Polymorphisms [J].Clin Pharmacol Ther, 2006,79(6):570-80.
[22]Baker S D, Verweij J, Cusatis G A, et al. Pharmacogenetic pathway analysis of docetaxel elimination [J], Clin Pharmacol Ther, 2009, 85(2):155-63.
[23]Puisset F, Chatelut E, Dalenc F, et al. Dexamethasone as a probe for docetaxel clearance [J]. Cancer Chemother Pharmacol, 2004, 54(3): 265-72.
[24]Dandamudi U B, Adams L M, Johnson B, et al. Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer [J]. Cancer Chemother Pharmacol, 2011, 67(4):783-90.
[25]van Schaik R H. CYP450 pharmacogenetics for personalizing cancer therapy [J]. Drug Resist Updat, 2008, 11(3):77-98.
[26]Nakajima Y, Yoshitani T, FukushimaUesaka H, et al. Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer [J]. Clin Pharmacol Ther, 2006,80(2): 179-91.
[27]Zhou S F, Zhou Z W, Huang M. Polymorphisms of human cytochrome P450 2C9 and the functional relevance [J].Toxicology, 2010, 278(2):165-88.
[28]Pulczynska A, Lukaszkiewicz J, Wojnar M, et al. Cytochrome P450 polymorphismmolecular,metabolic and pharmacogenetic aspects. IV. Application of long polymerase chain reaction for identification of CYP2D6 gene duplication [J]. Acta Pol Pharm, 2011, 68(1):9-13.
[29]Barginear M F, Jaremko M, Peter I, et al. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: Effect on active metabolite isomers and the antiestrogenic activity score [J]. Clin Pharmacol Ther, 2011, 90(4):605-11.
相似文献/References:
[1]杨秀芬,钟正贤,廖梅春,等.蛇葡萄素与苯并芘合用对大鼠肺组织内CYP和GST基因表达的影响[J].中国药理学通报,2010,(01):135.
YANG Xiu fen,ZHONG Zheng xian,LIAO Mei chun,et al.Effect of ampelopsis and benzo(a)pyrene coadministration on genes expression of CYP and GST in lung tissues of rats[J].Chinese Pharmacological Bulletin,2010,(03):135.
[2]马晶晶,李金恒,曹晓梅,等.基因多态性对奥美拉唑药动学与相对生物利用度的影响[J].中国药理学通报,2010,(02):258.
MA Jing jing,LI Jin heng,CAO Xiao mei,et al.Effects of CYP2C19 polymorphism on pharmacokinetic profile and comparative bioavailability of omeprazole[J].Chinese Pharmacological Bulletin,2010,(03):258.
[3]杨静,乔海灵.过敏反应与HLA基因多态性[J].中国药理学通报,2008,(04):0.
YANG Jing,QIAO Hai Ling.Correlation between allergy and HLA genetic polymorphism[J].Chinese Pharmacological Bulletin,2008,(03):0.
[4]杨静,乔海灵.青霉素特异性IgE抗体的种类与HLADRB基因多态性[J].中国药理学通报,2008,(06):0.
YANG Jing,QIAO Hai ling.Correlation of HLADRB genetic locus with penicillinspecific IgE antibodies[J].Chinese Pharmacological Bulletin,2008,(03):0.
[5]陈豪,谭志荣,周宏灏.含黄素单氧化酶3(FMO3)结构、功能及其基因多态性的研究进展[J].中国药理学通报,2008,(10):0.
CHEN Hao,TAN Zhi rong,ZHOU Hong hao.Advance in flavincontaining monooxygenase 3 (FMO3):structure/function and genetic polymorphisms[J].Chinese Pharmacological Bulletin,2008,(03):0.
[6]余敏,周宏灏,刘昭前.糖尿病肾病相关基因研究进展[J].中国药理学通报,2008,(11):0.
YU Min,ZHOU Hong hao,LIU Zhao qian.Progress in related genes of diabetic nephropathy[J].Chinese Pharmacological Bulletin,2008,(03):0.
[7]李慧华,杨敏,余敏,等.β3AR Trp64Arg遗传多态性对T2DM患者罗格列酮疗效的影响[J].中国药理学通报,2009,(03):0.
LI Hui hua,YANG Min,YU Min,et al.The effect of β3AR Trp64Arg on rosiglitazone response in T2DM patients[J].Chinese Pharmacological Bulletin,2009,(03):0.
[8]杨秀芬,钟正贤,廖梅春,等.蛇葡萄素与苯并芘合用对大鼠肝组织内CYP和GST基因表达的影响[J].中国药理学通报,2009,(07):0.
YANG Xiu fen,ZHONG Zheng xian,LIAO Mei chun.Effect of ampelopsis and benzo(a)pyrene coadministration on gene expression of CYP and GST in liver tissues of rats[J].Chinese Pharmacological Bulletin,2009,(03):0.
[9]庄笑梅,林庆辉,李春正,等.罗通定在人、比格犬和大鼠肝微粒体代谢转化的体外比较研究[J].中国药理学通报,2009,(09):0.
ZHUANG Xiao mei,LIN Qing hui,LI Chun zheng,et al.In vitro comparison of rotundine metabolism in liver microsomes of human,dog and rat[J].Chinese Pharmacological Bulletin,2009,(03):0.
[10]艾常虹,孙汉雄,李 桦,等.中药有效成分对细胞色素P450酶的抑制活性评价[J].中国药理学通报,2011,(04):519.
AIChang-hong,SUN Han-xiong,LIHua,et al.In vitro inhibition of cytochrom e P450activities by active constituents of Chinese herbal drugs [J].Chinese Pharmacological Bulletin,2011,(03):519.